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ABSTRACT   26 
 27 
We have shown in vitro that thyroid hormones (THs) regulate the balance between 28 
proliferation and apoptosis of T lymphoma cells. The effects of THs on tumor 29 
development have been studied, but the results are still controversial. Here, we show the 30 
modulatory action of thyroid status on the in vivo growth of T lymphoma cells. For this 31 
purpose, euthyroid, hypothyroid and hyperthyroid mice were inoculated with EL-4 cells 32 
to allow the development of solid tumors. Tumors in the hyperthyroid animals exhibited 33 
a higher growth rate, as evidenced by the early appearance of palpable solid tumors and 34 
the increased tumor volume. These results are consistent with the rate of cell division 35 
determined by staining the tumor cells with CFSE. Additionally, the hyperthyroid mice 36 
exhibited reduced survival. The hypothyroid mice were not significantly different from 37 
the euthyroid controls in these parameters. Additionally, only tumors from the 38 
hyperthyroid animals had increased expression levels of PCNA and active caspase 3. 39 
Also, the differential expression of cell cycle regulatory proteins was observed. The 40 
levels of cyclins D1 and D3 were augmented in the tumors of the hyperthyroid animals, 41 
whereas the cell cycle inhibitors p16/INK4A and p27/Kip1 and the tumor suppressor 42 
p53 were increased in the hypothyroid mice. Intratumoral and peritumoral 43 
vasculogenesis was increased only in the hyperthyroid mice. Therefore, we propose that 44 
the thyroid status modulates the in vivo growth of EL-4 T lymphoma through of the 45 
regulation of cyclin, cyclin-dependent kinase inhibitor, and tumor suppressor gene 46 
expression, as well as the stimulation of angiogenesis. 47 
 48 
 49 
 50 
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INTRODUCTION     51 
 52 
Thyroid hormones (THs) exert a wide variety of effects on lymphocyte function, and 53 
their regulation of tumor processes has also been described. Thus, alterations of the 54 
thyroid axis during the course of neoplastic illness, as well as the actions of THs on 55 
tumor growth, have been suggested. However, the effect of thyroid status on the 56 
evolution of tumors is controversial, and the mechanisms involved remain unknown. It 57 
has been reported that hypothyroidism can be a risk factor for the development of liver 58 
and breast cancer in humans (Reddy et al., 2007). Moreover, the use of levothyroxine, a 59 
synthetic T4 hormone commonly used to treat thyroid disease, was associated with a 60 
significantly reduced risk of colorectal cancer (Rennert et al., 2010). However, it was 61 
also shown that hypothyroid patients have a lower incidence of mammary carcinoma 62 
(Cristofanilli et al., 2005), and deprivation of THs decreased the growth rates of solid 63 
tumors, while thyroid hormone supplementation increased it (Guernsey et al., 1980; 64 
Hercbergs et al., 2010). Prospective studies to date have also yielded conflicting results. 65 
In fact, several studies have suggested that subclinical hyperthyroidism increases the 66 
risk of certain solid tumors, but spontaneous hypothyroidism delays the onset and 67 
reduces the aggressiveness of cancers (Hercbergs et al., 2010). However, a recent meta-68 
analysis showed no association between hypothyroidism and an increased risk for breast 69 
cancer (Angelousi et al., 2012). Thus, the heterogeneity of the analyzed studies 70 
precludes firm conclusions. Martínez-Iglesias et al. (2009) showed that hypothyroidism 71 
resulted in a decreased rate of solid tumor growth, as well as an increase in the 72 
development and number of metastases, in murine xenograft models of human 73 
hepatocarcinoma and breast cancer. However, low levels of circulating THs, induced by 74 
stress, enhanced tumor progression in mice, effect that was reversed following T4 75 
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administration (Frick et al., 2009).  Through in vitro studies we have demonstrated that 76 
culturing T lymphoma cells for 24 to 72 hours in the presence of THs increased cell 77 
proliferation via the activation of intracellular growth-related signaling pathways 78 
(Barreiro Arcos et al., 2006 and 2011). However, long term exposure to T4 (15 days of 79 
culture or more) leads to T lymphoma cell apoptosis (Mihara et al., 1999, Barreiro 80 
Arcos et al., 2013).  81 
Cell cycle regulatory proteins such as cyclins, cyclin-dependent kinases (Cdk), Cdk 82 
inhibitors (CdkI) and tumor suppressor proteins play important roles in tumor growth 83 
and progression. The expression of cyclins D1, D2, D3 are required for the progression 84 
from G0 to G1, E2 is necessary for G1 to S phase transition and B1 for G2 to M. These 85 
cyclins bind to their corresponding Cdks to form active complexes that induce the 86 
expression of a large number of cell cycle regulatory genes. Additionally, tumor 87 
suppressor genes inhibit cyclin-Cdks complexes leading to cell cycle arrest.  88 
Both TH-mediated up- or down-regulation of cyclins were demonstrated in several 89 
tissues (Ledda-Columbano et al., 2005; Verga-Falzacappa et al., 2012; Chattergoon et 90 
al., 2007). Also, it has been shown TH-mediated regulation of cyclin-Cdk complexes 91 
leqading to cell arrest (Toms et al., 1998) or to cell differentiation (Ballock et al., 2000).  92 
Alisi et al. (2005) showed in vivo that hyperthyroidism increases the levels of cyclin D1, 93 
E and A and the activity of cyclin-cdk complexes, and decreases the levels of cdk 94 
inhibitors, such as p16/INK4A and p27/Kip1. Also, they demonstrated that 95 
hypothyroidism induces contrary effects and that THs modulate the expression of the 96 
tumor suppressor genes p53 and p73, both involved in apoptosis and growth arrest. So 97 
the possibility that thyroid status influence tumor growth by altering the expression of 98 
cyclin, Cdks, CdkI or tumor suppressor genes deserves to be explored.  99 
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The development of solid tumors requires the formation of new blood vessels. 100 
Numerous studies have demonstrated that the thyroid status modulates angiogenesis, but 101 
the results of these studies are controversial. Kucharz et al. (2003) showed that 102 
increased or decreased levels of endostatin, a natural inhibitor of angiogenesis, were 103 
associated with hyperthyroidism and hypothyroidism, respectively. Additionally, 104 
increased serum levels of angiogenic molecules were found in autoimmune thyroid 105 
diseases (Figueroa-Vega et al., 2009). The recent description of a plasma membrane 106 
receptor for THs that could mediate the proliferative action of the hormone in blood 107 
vessels and tumor cells could shed some light on this matter (Cheng et al., 2010).  108 
Based on this background, the aim of this work was to study the effects of thyroid status 109 
on T cell lymphoma growth in vivo in euthyroid, hyperthyroid or hypothyroid syngeneic 110 
mice, thus deepening our understanding of the mechanisms involved in TH action, 111 
particularly those related to cell cycle progression and tumor angiogenesis.   112 
 113 
MATERIALS AND METHODS 114 
 115 
 Animal models 116 
 117 
Inbred female C57BL/6J (H-2
b
) mice, 2-3 months old, were bred and kept at the 118 
Instituto de Investigaciones Biomédicas (BIOMED, CONICET-UCA, Buenos Aires, 119 
Argentina) in accordance with the ARRIVE Guidelines (Kilkenny et al., 2010). All 120 
experimental protocols were approved by the Institutional Committee for the Care and 121 
Use of Laboratory Animals, School of Medicine. Animals were kept in a 12-hour light-122 
dark cycle with a controlled temperature between 18 and 22°C, with ad libitum access 123 
to food and water. 124 
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Models of hyperthyroidism or hypothyroidism were developed in accordance to Klecha 125 
et al. (2005 and 2006). Briefly, hyperthyroidism was achieved by daily treatment with 126 
0.012 mg/ml T4 (Sigma-Aldrich, St. Louis, Mo., USA) in the drinking water for 1 127 
month, and hypothyroidism by similar treatment with 0.5 mg/ml of propylthiouracil 128 
(PTU; Sigma-Aldrich) for 15 days.  129 
 130 
Hormone determinations 131 
 132 
Blood was collected from the tail vein using a capillary tube coated with anticoagulant, 133 
and plasma was obtained by centrifugation. The plasma levels of T3 and T4 were 134 
determined using commercial radioimmunoassay (RIA) kits with specific antibodies 135 
(Immunotech, Praga, Czech Republic) according to the manufacturer’s instructions. The 136 
plasma TSH level was assayed using an ELISA kit (Uscn Life Science Inc., Wuhan, 137 
Hubei, Republic of China).  138 
 139 
Lymphoma model 140 
 141 
The tumor cell line EL-4 (ATCC, Catalog Number TIB-39), a mouse T-cell lymphoma 142 
expressing the H-2
b
 and Thy-1.2 haplotype, as well as the CD3
+
 and αβ T-cell receptors; 143 
was routinely tested by flow cytometry with specific antibodies against the 144 
corresponding surface markers. These cells were cultured at an optimal concentration 145 
(1–5×10
5
 cells/ml) in RPMI-1640 medium supplemented with 10% v/v fetal bovine 146 
serum (FBS), 2 mmol l
-1
 glutamine and 100 mg/ml of streptomycin (all from Life 147 
Technologies, NY, USA). Euthyroid, hyperthyroid or hypothyroid C57BL/6J syngeneic 148 
animals were injected subcutaneously with 3x10
5
 EL-4 cells in 200 µl of PBS to 149 
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generate a solid tumor. After cell inoculation, hormonal treatments were maintained 150 
until the end of the experiments. 151 
 152 
Tumor development 153 
 154 
Tumor length and width were measured daily using calipers. Tumor volume was 155 
calculated by the equation V= (π/6)×length×width
2
 (Frick et al., 2011). The rate of 156 
tumor growth was quantified by carboxyfluorescein succinimidyl ester (CFSE) staining 157 
(Vybrant CFDA SE Cell Tracer Kit, Life Technologies; Lyons et al., 1999). The cells 158 
were labeled as previously described (Barreiro Arcos et al., 2006). The stained cells 159 
(3x10
5
 cells/0.2 ml PBS) were subcutaneously inoculated into C57BL/6J mice with 160 
different thyroid status. Ten days later, the mice were sacrificed, and the solid tumors 161 
were extracted and dispersed in a metal mesh. The tumor cell suspensions were fixed in 162 
3.7 % v/v formaldehyde and analyzed by flow cytometry (BD FACSCalibur) at 492 nm. 163 
The estimated cell division time was calculated from the mean fluorescence intensity 164 
(MFI) values of the EL-4 cells using the following equation: T1/2 = [ k x time post-165 
inoculation ] / ln T - ln T0, where T1/2 is the cell doubling time, k is the constant of value 166 
0.693, T is the MFI of the CFSE quantified at ten days post-inoculation and T0 is the 167 
MFI of the CFSE of EL-4 cells prior to inoculation (Frick et al., 2009). 168 
Animal survival analysis was determined using Kaplan-Meier curves. Briefly, the mice 169 
were monitored every day and euthanized according to the guidelines for animal care 170 
when they showed signs of suffering, hypothermia and slow locomotion, which is 171 
characteristic of animals that are close to death (Massari et al., 2013). All animals had 172 
approximately the same tumor burden, without metastatic dissemination when 173 
sacrificed. 174 
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Tumor histopathology  175 
 176 
Solid tumors growing in euthyroid, hyperthyroid and hypothyroid mice were excised, 177 
and fixed in 3.7 % v/v formaldehyde overnight. Then, the samples were embedded in 178 
paraffin and cut into 4 µm thick serial sections using a microtome. Tumor morphology 179 
and histopathological characteristics were examined after hematoxylin-eosin (H&E) and 180 
Masson’s trichrome staining. The number of mitotic cells was quantified as the number 181 
of cells with visible chromosomes in 630x magnification fields. Vascularization was 182 
determined using Masson’s trichrome staining, and the stained sections were screened 183 
at 50 x magnification to identify the largest vascular areas around the tumor. In these 184 
areas, intratumoral vascularity was evaluated by counting the vessels in 10 random 185 
fields from inside the tumor at 630 x magnification. Light microscopy was performed 186 
on an Axiolab Karl Zeiss microscope (Göttingen, Germany). Photographs were taken at 187 
630 x magnifications using a Canon PowerShot G5 camera (Tokyo, Japan). 188 
Intratumoral vascularization was also analyzed by immunohistochemistry. 189 
 190 
Immunohistochemistry 191 
 192 
Cell proliferation, apoptosis and angiogenesis markers were examined by 193 
immunohistochemistry in tumor tissue sections, prepared as previously described. The 194 
antigen retrieval was performed in citrate buffer (10 mmol l
-1
, pH 6.0) at 100°C, and 195 
endogenous peroxidase activity was blocked with 3% v/v H2O2 in distilled water. After 196 
blocking, the tissues were incubated with the following primary antibodies overnight in 197 
a humidified chamber at 4ºC: mouse anti-proliferating cell nuclear antigen (PCNA, 198 
1:100, Santa Cruz Biotechnology, Inc., Dallas, Texas, USA), rabbit anti-cleaved 199 
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caspase-3 (1:100, Abcam, Cambridge, MA, USA) and rabbit anti-CD31 (1:200, 200 
Abcam). Immunoreactivity was detected using horseradish peroxidase-conjugated anti-201 
mouse or anti-rabbit antibodies and was visualized by diaminobenzidine staining 202 
(Sigma-Aldrich). Serial sections from selected positive cases were used as controls, by 203 
replacing the primary antibody with either a normal mouse or rabbit IgG or PBS in the 204 
staining procedure. No signal was detected in these control samples. 205 
 206 
Angiogenesis 207 
 208 
EL-4 cells (3x10
5
) were subcutaneously inoculated into the left flank of euthyroid, 209 
hyperthyroid and hypothyroid mice. On day 6, when the tumors were palpable in the 210 
three groups, mice were sacrificed, and the blood vessels supplying the tumor were 211 
quantified using microscopy, as previously described by Ferrando et al. (2011). It is 212 
worth noting that it is not possible to accurately evaluate peritumoral angiogenesis at 213 
day 10, because of the tumor mass great size. To evaluate the level of angiogenesis 214 
associated with the tumor, the number of blood vessels in the tumor tissue area was 215 
normalized to the number of vessels in the normal dermal tissue area present in the right 216 
flank (control), which was inoculated with sterile PBS solution.  217 
 218 
Reverse transcription (RT) and real time quantitative polymerase chain reaction 219 
(qPCR) 220 
 221 
After the animals were sacrificed, solid tumors were removed and immediately 222 
homogenized in Tri-Reagent (Genbiotech SRL, Buenos Aires, Argentina) to isolate the 223 
RNA, according to the manufacturer's instructions. The RNA pellets were dissolved in 224 
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RNase-free water and the RNA concentration was quantified by measuring the 225 
absorbance at 260 nm (Nanodrop ND-1000, UK). Complementary DNA (cDNA) was 226 
synthesized by retrotranscription using the Omniscript kit (Qiagen, Germantown, MD, 227 
USA) following the manufacturer's instructions using 2 µg of total RNA and 1 µmol l
-1
 228 
oligodeoxythymidine12-18 (Biodynamics SRL, Buenos Aires, Argentina). The PCR 229 
reactions were performed using a commercial master mix for Real-Time PCR 230 
containing SYBR Green fluorescent dye (Biodynamics SRL) in a total volume of 25 µl, 231 
which contained 10 pmol of each primer and 1µl of cDNA. The reactions were carried 232 
out in a Rotor Gene-6000 DNA thermal cycler (Corbett, Life Sciences, Sydney, 233 
Australia). The cycling conditions were 95 °C for 15 min, followed by 40 cycles of 234 
denaturation at 95 °C for 10 s, annealing at 60 °C for 15 s, and extension at 72 °C for 30 235 
s. The primer sequences (Biodynamics SRL), shown in Table 1, were designed using 236 
the Primer Express software version 3.0 (Applied Biosystems, California, USA). 237 
Quantification of the target gene expression was performed using the comparative cycle 238 
threshold (Ct) method (Livak and Schmittgen, 2001). An average Ct value was 239 
calculated from the duplicate reactions and normalized to the expression of β2-240 
microglobulin, and the ∆∆Ct value was then calculated. 241 
 242 
Immunoblot analysis  243 
 244 
The tumor mass was excised, and the tissue cells were dissected in a metal mesh. The 245 
tumor cells were lysed for 30 min at 4°C in lysis buffer (Barreiro Arcos et al., 2013). 246 
After centrifugation at 14,000 g for 15 min at 4°C, whole cell protein extracts obtained 247 
(30 µg) were separated by SDS-PAGE on 10% v/v polyacrylamide gels using standard 248 
methods (Klecha et al. 2006) and transferred to PVDF membranes. Then the 249 
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membranes were incubated for 18 h with appropriate dilutions of primary antibodies: 250 
mouse anti-PCNA or rabbit anti-cleaved caspase-3 (Abcam, Cambridge, MA, USA), 251 
rabbit anti-cyclin D1, mouse anti-cyclin D3 and anti-cyclin E1 antibodies (Cell 252 
Signaling Technology, MA, USA), rabbit anti-p16/INK4A, mouse anti-p27/Kip1 and 253 
mouse anti-p53 antibodies (Santa Cruz Biotechnology). The membranes were then 254 
incubated with anti-rabbit (Abcam) or anti-mouse (Santa Cruz Biotechnology) 255 
secondary antibodies conjugated to horseradish peroxidase for 1 h. An enhanced 256 
chemiluminescence system (Amersham
TM
 ECL
TM
 Prime Western blotting detection 257 
reagent; GE Healthcare, Buckinghamshire, UK) was used to detect the proteins. A 258 
rabbit anti-β actin antibody (Santa Cruz Biotechnology) was used as a control for 259 
protein loaded. Densitometry analysis of the bands was performed using the ImageJ 260 
software (version 5.1, Silk Scientific Corporation, NIH, Bethesda, MA). The 261 
densitometry units for the protein bands were normalized to the corresponding β actin 262 
bands. 263 
 264 
Statistical analysis 265 
 266 
The means of the different experimental groups were analyzed for statistical 267 
significance using GraphPad PRISM 4.0 Version for Windows (GraphPad Software 268 
Inc., La Jolla, California); a two-way Analysis of Variance (ANOVA) followed by 269 
Tukey’s post hoc analysis was used to assess statistical significance. The differences 270 
between the means were considered significant if p<0.05. The results are expressed as 271 
the mean ± standard error (SE). Survival curves were created using the Kaplan–Meier 272 
method, and the survival rates were compared using the Log-rank test.  273 
 274 
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RESULTS 275 
 276 
Thyroid status regulates tumor growth  277 
 278 
The progression of the EL-4 lymphoma cells growing in vivo in syngeneic mice with 279 
different thyroid status was evaluated. The plasma levels of T3, T4 and TSH were 280 
determined to check the efficacy of the T4 and PTU treatments. The hyperthyroid mice 281 
showed high plasma levels of T3 and T4 and low levels of TSH, while the hypothyroid 282 
mice showed lower T3 and T4 levels, but higher levels of TSH than the euthyroid mice 283 
(Figure 1 A). After EL-4 cells inoculation all animals develop solid tumors. The 284 
hyperthyroid mice showed a significant increase in EL-4 lymphoma growth, while the 285 
hypothyroid showed no statistically significant differences with respect to the tumors in 286 
euthyroid controls (Figure 1 B, C and D). Additionally, Kaplan-Meier survival curves 287 
(Figure 1 E) showed a significant reduction in the survival of the hyperthyroid mice 288 
compared to the hypothyroid and euthyroid mice, indicating a worse prognosis. The 289 
hyperthyroid mice showed a survival of 50 % at 17.2±1.4* days, while the hypothyroid 290 
and euthyroid mice showed a survival of 50% at 22.1±1.5 and 21.3±1.7 days, 291 
respectively (*p<0.05 vs. the euthyroid or hypothyroid mice). Because the hyperthyroid 292 
animals showed increased tumor development compared to the control and hypothyroid 293 
mice, the kinetics of EL-4 cell division were evaluated. For this analysis, EL-4 cells 294 
were stained with CFSE prior to inoculation, and the mean fluorescence intensity (MFI) 295 
of the CFSE labeled-cells in the tumors was evaluated by flow cytometry, ten days post-296 
inoculation. The EL-4 cells growing in the hyperthyroid mice exhibited a lower MFI 297 
than the tumor cells in the control or hypothyroid animals (Figure 2 A and B). 298 
Consistent with these findings, the hyperthyroid mice showed an increased rate of cell 299 
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proliferation respect to the euthyroid and hypothyroid mice (Figure 2C). No significant 300 
differences were observed between the hypothyroid and euthyroid groups. The increase 301 
in the cell division rate that was observed in the hyperthyroid mice could contribute to 302 
the rapid tumor growth and the lower survival of these animals.  303 
 304 
Effects of thyroid status on the histological characteristics of the tumor tissue 305 
 306 
The histopathological characteristics of the tumor tissue were examined using sections 307 
stained with hematoxylin-eosin (H&E) and Masson’s trichrome. Tumor sections from 308 
all of the experimental groups showed undifferentiated lymphoma cells with aberrant 309 
nuclei and marked anisokaryosis and karyorrhexis, as well as the presence of connective 310 
tissue trabeculae and infiltrates in the muscle tissue. The tumors from the hyperthyroid 311 
mice showed an increased number of mitotic cells, as well as the presence of cystic 312 
areas and some levels of necrosis. The tumors from the hypothyroid mice exhibited a 313 
lower number of mitotic cells and fewer cystic formations, but areas of diffuse 314 
hemorrhage and vascular damage with high levels of necrosis were also observed. The 315 
absence of necrosis and a low number of cystic formations were found in the tumors 316 
from the euthyroid mice (Figure 3 A and B). Additionally, intratumoral vascularization 317 
in the tumor sections was evaluated using the Masson’s trichrome staining and 318 
immunostaining with an anti-CD31 antibody. The tumors from the hyperthyroid mice 319 
exhibited more vascularization, with large vessels and increased expression of the CD31 320 
vascular endothelium marker, with respect to those in euthyroid or hypothyroid animals 321 
(Figure 3 A and C). 322 
 323 
Thyroid status modulate tumor angiogenesis 324 
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 325 
Peritumoral angiogenesis was quantified in the three experimental groups 6 days after 326 
EL-4 cell inoculation, when the tumors were palpable. The hyperthyroid mice displayed 327 
an increased number of blood vessels surrounding the tumor tissue (Figure 3 D and E). 328 
Additionally, this group showed a higher angiogenesis level in the normal dermal tissue 329 
(Figure 3 D and F, right flank). Non-significant differences were found between the 330 
euthyroid and hypothyroid animals. 331 
 332 
Thyroid status alters the balance between proliferation and apoptosis in the tumor 333 
cells 334 
 335 
The balance between the proliferation and apoptosis of the T lymphoma cells in the 336 
tumors growing in euthyroid, hyperthyroid or hypothyroid mice was evaluated. The 337 
tumors from the hyperthyroid mice highly expressed the PCNA marker and cleaved 338 
caspase-3 in the non-necrotic areas of the tumor tissue, as shown by 339 
immunohistochemistry analysis (Figure 4 A). The protein levels of both markers were 340 
also quantified using western blot analysis. The tumors from the hypothyroid and 341 
euthyroid mice showed no significant differences in the levels of PCNA or cleaved 342 
caspase-3 (Figure 4 B and C). Because the increase in the level of PCNA was greater 343 
than the increase in cleaved caspase-3 within the tumor sample, we determined the ratio 344 
between both markers. Figure 4 D shows that this ratio was increased in the 345 
hyperthyroid mice with respect to the other two groups. These results could explain the 346 
observed differences in tumor growth among the animals with different thyroid status. 347 
 348 
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Thyroid status modulates the expression of proteins associated with cell cycle 349 
progression 350 
 351 
Because we found that the thyroid status modulates the rate of cell division, the 352 
expression levels of several genes related to the regulation and the promotion of the cell 353 
cycle were analyzed in the solid tumors growing in mice with different thyroid status.  354 
The tumors from the hyperthyroid mice showed increased cyclin D1, D3 and E1 mRNA 355 
levels. We found no differences in the levels of cyclin A, B and D2 mRNA at this time. 356 
The tumors from the hypothyroid mice showed no significant differences in the mRNA 357 
levels of the cyclins with respect to the euthyroid control mice (Figure 5 A). 358 
Additionally, we observed increased levels of the cyclin D1 and D3 proteins in the 359 
hyperthyroid tumors (Figure 5 B and C). The CdkIs are key regulators of cell cycle 360 
progression. Thus, we also evaluated their mRNA expression. Only the expression 361 
levels of the p16/INK4A and p27/Kip1 genes were modulated by the thyroid status of 362 
the animals carrying the tumor. The tumors from the hypothyroid mice showed 363 
increased p16/INK4A mRNA expression with respect to the euthyroid animals and 364 
increased p27/Kip1 mRNA expression with respect to the euthyroid or hyperthyroid 365 
animals (Figure 6 A). Additionally, the increased expression of these proteins was 366 
observed only in the hypothyroid animals, with respect to the hyperthyroid animals, 367 
according to the western blot results (Figure 6 C and D). Non-significant differences in 368 
the mRNA expression of CdkIs were observed in the solid tumors from the 369 
hyperthyroid mice compared to the euthyroid mice (Figure 6 A). However, a decrease 370 
in the protein levels of p27/Kip1 was observed by western blot analysis (Figure 6 C 371 
and D).  372 
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In the case of the tumor suppressor genes, which protect the cells from malignant 373 
transformation by inhibiting cell cycle progression, a significant increase in the mRNA 374 
expression of p53 was observed in the tumors from the hypothyroid mice compared to 375 
the tumors from the hyperthyroid group (Figure 6 B). This was accompanied by an 376 
increase in its protein expression (Figure 6 C and D). The tumors from the 377 
hyperthyroid mice showed no significant differences in the mRNA expression of the 378 
tumor suppressor genes (Figure 6 B), but a decrease in p53 protein, with respect to 379 
euthyroid controls, was observed (Figure 6 C and D).  380 
 381 
DISCUSSION 382 
 383 
Despite the controversial results on the effect of thyroid status regulation on tumor 384 
growth, we show here that the development of T cell lymphoma in syngeneic mice is 385 
affected by a thyroid hormone-mediated increase in tumor T cell proliferation. We 386 
showed that hyperthyroid mice developed larger tumors than the control or hypothyroid 387 
animals, effect that was impaired by reverting to euthyroid conditions (data not shown). 388 
This was due to an increased cell proliferation rate. In fact, we have already shown that 389 
THs have different effects on the murine BW5147 T lymphoma cell line, depending on 390 
the time of exposure. THs increased in vitro tumor cell proliferation through the 391 
activation of PKCζ and NOS and the increased expression of iNOS when exposed to 392 
THs for less than 5 days in culture (Barreiro Arcos et al., 2006). Additionally, we 393 
showed that this proliferative activity was mediated by genomic and non-genomic 394 
mechanisms involving ERK activation and thyroid hormone receptor regulation 395 
(Barreiro Arcos et al., 2011). However, prolonged treatment with THs led to cell death 396 
by apoptosis (Barreiro Arcos et al., 2013). Similar findings were observed in the EL-4 397 
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cell line (data not shown). Additionally, other in vitro studies in human breast cancer 398 
lines (Tang et al., 2004), papillary and follicular thyroid cells (Lin et al., 2007), glioma 399 
U-87 MG cells (Lin et al., 2009) and lung cancer cells (Meng et al., 2011) showed that 400 
exposure to physiological concentrations of T3 and T4 induced cell proliferation 401 
through the activation of ERK1/2.  402 
Moreover, the tumor-bearing hyperthyroid mice exhibited a decreased survival rate. The 403 
increased cell division rate that was observed in the tumors from the hyperthyroid mice 404 
could contribute to the rapid tumor growth and the reduced survival of these animals. It 405 
is unlikely that animals died as a result of the effects of hyperthyroidism, as 406 
hyperthyroid animals without tumor live for significantly greater time than the tumor-407 
bearing animals. However, we cannot rule out that the stress generated by the tumor 408 
development could negatively influence the survival of hyperthyroid animals (Frick et 409 
al., 2009). 410 
No differences were observed between the tumors grown in the euthyroid and 411 
hypothyroid mice.  412 
The balance between the proliferation and apoptosis of the tumor cells is considered an 413 
indicator of tumor growth; therefore, we analyzed these parameters in our animal 414 
models. An increased number of cells expressing the PCNA cell proliferation marker 415 
and active caspase-3 were found in the tumors from the hyperthyroid animals with 416 
respect to the controls, and the ratio between the levels of these proteins was also higher 417 
in the hyperthyroid mice. Additionally, we observed a significant increase in the 418 
number of mitotic cells in the H&E-stained tissue sections of the hyperthyroid tumors, 419 
as well as localized phenomena of apoptosis that could be observed as cystic areas 420 
without cellular content. This last observation could be explained because the fast speed 421 
of cell proliferation may cause an insufficient arrival of nutrients and oxygen to the 422 
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tumor tissue inducing apoptotic areas. Both phenomena occur together, but our results 423 
indicate that the proliferative effect is stronger than the apoptotic action, which is in 424 
agreement with the increased tumor growth observed in this group. 425 
Neovascularization is an essential process for the survival of tumor cells and tumor 426 
growth. We next examined peritumoral and intratumoral angiogenesis in the tumors 427 
from the euthyroid, hyperthyroid and hypothyroid mice. Peritumoral angiogenesis was 428 
quantified in the tumors grown in our experimental models 6 days after EL-4 cell 429 
inoculation, when the tumor volume was only a few millimeters. The tumors from the 430 
hyperthyroid mice showed a greater irrigation of blood vessels than the tumors from the 431 
euthyroid or hypothyroid animals. Additionally, the hyperthyroid mice displayed an 432 
increased number of blood vessels in the contralateral flank, which was not inoculated 433 
with tumor cells. It is worth to notice that hypothyroid mice showed greater levels of 434 
necrosis in their tumors than the other studied groups, despite having similar levels of 435 
angiogenesis to those observed in euthyroid animals. Similar results were obtained by 436 
Martinez et.al (2009), who showed that the reduced tumor volume in hypothyroid hosts 437 
correlated with a lower proliferation of the tumors, which was accompanied also by 438 
enlargement of the necrotic area of the tumors. This is probably as a result of THs 439 
deficiency. In fact, THs are necessary growth factors involved in T cell lymphoma 440 
proliferative and survival signals (Barreiro Arcos et. al, 2006 and 2011), so the lack of 441 
THs would induce cell death signaling that leads to the formation of the necrotic areas 442 
observed in these tumors.   443 
Intratumoral vascularity was evaluated by counting the blood vessels inside the tumor 444 
10 days after inoculation with the tumor cells. The tumor tissue from the hyperthyroid 445 
animals showed a larger number of endothelial cells (CD31+), which was in agreement 446 
with the increased number of blood vessels shown by Masson’s trichrome staining. The 447 
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hypothyroid mice displayed similar levels of intratumoral and peritumoral angiogenesis 448 
as the euthyroid controls. Our results are supported by numerous works that suggest the 449 
involvement of the THs in the modulation of angiogenesis. Patients with Grave’s 450 
disease have high serum levels of angiogenic molecules, which are significantly 451 
decreased after treatment with antithyroid drugs (Figueroa-Vega et al., 2009). 452 
Additionally, patients with Grave’s disease exhibit an increased microvessel density 453 
(Tseleni-Balafouta et al., 2006) and angiogenic vascular endothelial growth factor 454 
serum levels (Iitaka et al., 1998). 455 
We showed that the hyperthyroid state induces tumor growth by accelerating the 456 
process of cell division. There is evidence that the THs modulate the progression of the 457 
cell cycle through the regulation of cell cycle regulatory proteins (Woodmansee et al., 458 
2006). We observed that the levels of cyclins D1 and D3 were increased in the tumors 459 
grown in the hyperthyroid animals. Increased cyclin D1, which regulates the entry into 460 
G1 phase of the cell cycle, has been widely linked to the regulation of the cell cycle by 461 
THs in various cell types (Verga Falzacappa et al., 2012; Ledda-Columbano et al., 462 
2006; Zhang et al., 2012). Several pieces of evidence have indicated that cyclins D1 and 463 
D3 are involved in T-cell lymphomagenesis and are important molecular markers of 464 
oncogenic potential in T cell lymphomas (Cheng et al., 2008; Teramoto et al., 1999). 465 
Furthermore, cyclin D3 overexpression is associated with a higher proliferation rate, as 466 
well as with lower p27/Kip1 and altered p53 expression (Møller et al., 2001). The 467 
positive regulation of cyclins D1 and D3 has been associated with a poor prognosis in 468 
patients with lymphoma (Zukerberg et al., 1995; Kanavaros et al., 2001; Mao et al., 469 
2006). Cyclin E1 is a key mediator of T-cell lymphomagenesis and regulates the 470 
transition between G1 and S phases (Geisen et al., 2003; Karsunky et al., 1999; 471 
Hosokawa et al., 1995; Kang-Decker et al., 2004); however, we observed an increase 472 
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only of the mRNA expression of cyclin E in the hyperthyroid animals, but we cannot 473 
rule out an increment of its protein levels at other time points. Hypothyroidism does not 474 
affect the expression pattern of the cyclins, as the cell division speed and tumor growth 475 
were similar to the tumors grown in the euthyroid animals.  476 
Previous reports indicated that the INK4 family is altered in lymphoma (Gallardo et al., 477 
2004; Baur et al., 1999; Nagasawa et al., 2006). We observed an increase in the mRNA 478 
and protein levels of p16/INK4A in the tumors from the hypothyroid mice compared to 479 
those from the hyperthyroid mice, but no significant differences were observed in 480 
p15/INK4B expression. The expression levels of p21/Cip1 were not modulated by 481 
thyroid status, even though it has been suggested that this protein is involved in the 482 
development of T cell lymphoma (Kanavaros et al., 2001), but we observed a decreased 483 
expression of p27/Kip1 in the tumors from the hyperthyroid animals compared to those 484 
from the hypothyroid animals, which is in agreement with several pieces of 485 
experimental evidence. In this regard, Cheng et al., (2008) found that p27/Kip1 486 
deficiency in transgenic mice leads to T-cell hyperplasia and the development of 487 
spontaneous T lymphomas, and Geisen et al., (2003) showed that the reduction in 488 
p27/Kip1 expression is involved in the T cell lymphomagenesis. 489 
Additionally, we evaluated the expression of the PTEN, Rb and p53 tumor suppressor 490 
genes, whose expression levels are often deregulated in T cell lymphomas (Kanavaros et 491 
al., 2001; Mao et al., 2006; Møller et al., 2002). We only observed a decrease in the 492 
expression of p53 in the tumors from the hyperthyroid animals compared to those from the 493 
hypothyroid or euthyroid animals, and this result was anticipated due to its key role in 494 
hematological malignancies (Kanavaros et al., 2001; Møller et al., 2002). The decreased 495 
expression of the p16/INK4A, p27/Kip1 and p53 proteins in the tumors from the 496 
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hyperthyroid mice could facilitate cell cycle progression and contribute to tumor 497 
growth. 498 
The results shown in this work are in agreement with in vivo studies investigating the 499 
modulation of cell cycle regulators in other physiological, non-neoplastic processes. 500 
Alisi et al. (2005) demonstrated that hyperthyroidism increased the expression of cyclins 501 
D1, E and A and decreased the expression of p16/INK4A and p27/Kip1 in a rat model of 502 
liver regeneration; this study also showed that hypothyroidism resulted in the reduced 503 
expression of these cyclins, as well as the increased expression of p16/INK4A, p27/Kip1 504 
and p53. 505 
Based on these results, we conclude that thyroid status can modulate T lymphoma EL-4 506 
growth through the regulation of cell cycle protein expression, which includes the 507 
cyclins, cyclin-dependent kinase inhibitors, and tumor suppressor genes, and through 508 
the up-regulation of angiogenesis. These results will contribute to a better understanding 509 
of the actions of THs during tumor development. 510 
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LEGENDS FOR FIGURES  768 
 769 
Figure 1: Effects of thyroid status on tumor progression. The plasma levels of 770 
thyroid hormones in euthyroid, hyperthyroid and hypothyroid mice were determined 771 
using an ELISA, as described in Materials and Methods (A). Euthyroid, hyperthyroid 772 
and hypothyroid mice were subcutaneously inoculated with 3x10
5
 EL-4 cells, and the 773 
volumes of the resulting solid tumors were measured (B). Representative photographs 774 
of the solid tumors grown in mice with different thyroid statuses 10 days after 775 
inoculation are shown (C). The tumor tissue weight removed at 10 days post-776 
inoculation was determined (D). Kaplan-Meier survival analysis was performed on the 777 
experimental groups subcutaneously inoculated with 3x10
5
 EL-4 cells (E). The values 778 
are expressed as the mean ± SE. *p<0.05 vs. the corresponding euthyroid mice. 779 
 780 
Figure 2: Effects of thyroid status on the rate of tumor cell division. EL-4 cells 781 
were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and were 782 
subcutaneously inoculated into euthyroid, hyperthyroid and hypothyroid mice. Ten 783 
days post-inoculation, the tumor tissue was removed, and the CFSE mean fluorescence 784 
intensities (MFIs) of the tumor cells were quantified using flow cytometry. 785 
Representative histograms of 4 independent experiments are shown. The histogram 786 
corresponding to T0 represents the CFSE fluorescence intensity of the EL-4 cells prior 787 
to inoculation into the animal models. The MFIs of the EL-4 cells grown in the 788 
euthyroid, hyperthyroid and hypothyroid mice are indicated in parentheses (A). The 789 
MFI of each experimental group is shown in the bar graph as a percentage of the MFI 790 
at T0 (B). The estimated cell division time is indicated in the table (C). The values are 791 
expressed as the mean ± SE. *p<0.01 vs. the euthyroid mice. 792 
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Figure 3: Effects of thyroid status on the histological characteristics of the tumor 793 
tissue and tumor angiogenesis. Solid tumors grown in euthyroid, hyperthyroid and 794 
hypothyroid mice were excised 10 days after tumor inoculation. The tumor tissue were 795 
fixed, embedded in paraffin and cut into serial sections using a microtome. Histological 796 
characteristics of the tumor tissue were examined in the tissue sections after staining 797 
with hematoxylin-eosin (H&E) and Masson’s trichrome. Vascularization in the tissue 798 
sections was evaluated using Masson’s trichrome and immunostaining with an anti-799 
CD31 antibody. Representative photographs from 4 independent trials using 5 animals 800 
per group are shown. The black arrows indicate the mitotic cells (H&E staining), blood 801 
vessels (Masson’s trichrome) or endothelial cells (CD31+ immunostaining), and the 802 
white arrows indicate the hemorrhagic areas (H&E staining) (A). The number of 803 
mitotic cells in the tissue sections stained with H&E was quantified. Ten random fields 804 
from each sample from each experimental group were analyzed (B). The number of 805 
blood vessels in the tissue sections stained with Masson’s trichrome solution was 806 
quantified. Intratumoral vascularity was evaluated by counting the number of blood 807 
vessels inside the tumor in 10 random fields (C). Angiogenesis was quantified in the 808 
solid tumors grown in euthyroid, hyperthyroid and hypothyroid mice 6 days after 809 
inoculation with EL-4 cells, as described in Materials and Methods. Representative 810 
solid tumors irrigated by blood vessels are shown (left flank). The right flanks of the 811 
mice without tumor inoculation are shown as controls (D). The number of blood 812 
vessels in the tumor tissue area was normalized to the number of vessels in the normal 813 
dermal tissue area present in the flank control, which was inoculated with sterile PBS 814 
solution (E). The average number of blood vessels in the control flank (without tumor) 815 
is shown in the bar graph (F). The values are expressed as the mean ± SE. **p<0.01 or 816 
*p<0.05 vs. the euthyroid mice or hyperthyroid mice. 817 
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Figure 4: Effects of thyroid status on the cellular proliferation and apoptosis of 818 
the tumor tissue. Tumor tissue sections from euthyroid, hyperthyroid or hypothyroid 819 
mice excised 10 days after EL-4 cell inoculation. Lymphoma cell proliferation and 820 
apoptosis were determined by immunohistochemistry using PCNA or active caspase-3 821 
antibodies. Representative photographs from 4 independent experiments using 5 822 
animals per group are shown (A). PCNA and active caspase-3 expression was 823 
evaluated by western blot analysis from the tumor tissue protein extracts. Actin was 824 
used as a protein loading control. The results are representative of 4 independent 825 
experiments (B). Densitometric results of the western blot analysis are shown in the bar 826 
graph (C). The ratio of PCNA and caspase-3 protein expression is shown (D). The 827 
values are expressed as the mean ± SE. *p<0.05 or **p<0.01 vs. the euthyroid mice. 828 
 829 
Figure 5: Effects of thyroid status on the expression of cell cycle regulatory 830 
proteins. Differential gene expression of the cyclins was observed in the tumor tissues 831 
from the euthyroid, hyperthyroid and hypothyroid mice. The mRNA expression of the 832 
cyclins was determined using qPCR, and the expression levels were normalized to the 833 
expression of the housekeeping gene β-actin; the ∆∆Ct method was used to calculate 834 
fold change (A). The expression of the cyclin proteins was evaluated using western blot 835 
analysis. Actin was used as a protein loading control. The results are representative of 4 836 
independent experiments (B). Densitometric results of the western blot analysis in the 837 
euthyroid, hyperthyroid and hypothyroid mice are shown in the bar graph (C). The 838 
values are expressed as the mean ± SE. *p<0.05 or **p<0.01 vs. the euthyroid mice. 839 
 840 
Figure 6: Effect of thyroid status on cyclin inhibitors and tumor suppressor 841 
proteins. The mRNA expression of the cyclin-dependent kinase inhibitors 842 
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(P15/INK4B, p16/INK4A, p21/Cip1 and p27/Kip1) was determined in the tumor 843 
tissues from the euthyroid, hyperthyroid and hypothyroid mice using qPCR analysis. 844 
Gene expression was normalized to the expression of the β-actin gene, and the ∆∆Ct 845 
method was used to calculate fold change (A). The mRNA expression of the tumor 846 
suppressor genes (p53, PTEN and Rb) as determined using qPCR analysis; expression 847 
was normalized to the expression of the β-actin gene, and the ∆∆Ct method was used to 848 
calculate fold change (B). Protein expression of the cyclin-dependent kinase inhibitors 849 
and the tumor suppressor proteins was analyzed using western blot analysis. Actin was 850 
used as a protein loading control. The results are representative of 4 independent 851 
experiments (D). Densitometric results of the western blot analysis are shown in the bar 852 
graph (E). The values are expressed as the mean ± SE. *p<0.05 vs. the euthyroid 853 
animals; #p<0.05 or ##p<0.01 vs. the hyperthyroid animals. 854 
 855 
 856 
 857 
 858 
 859 
 860 
 861 
 862 
 863 
 864 
 865 
 866 
 867 
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Table 1: Primer sequences used for real time RT-PCR analysis.  
 
Gene Primer Sequences 
Tm 
(°C) 
Cyclin A2 
 
5’-GGCCAGCTGAGCTTAAAGAAAC-3’  
5’-CGGGTAAAGAGACAGCTGCAT-3’ 
58.3 
58.1  
Cyclin B1 
 
5’-AGGGTCGTGAAGTGACTGGAAACA-3’ 
5’-CTTGGGCACACAACTGTTCTGCAT-3’ 
60.2 
60.3 
Cyclin D1 
 
5’-CCAAAACCATTCCATTTCAAAG-3’ 
5’-CCAACACACACCAGCAACACT-3’  
57.2     
58.1 
Cyclin D2 
 
5’-ACTTCAAGTTTGCCATGTACCCGC-3’ 
5’-TTCAGCAGCAGAGCTTCGATTTGC-3’ 
60.1 
60.2 
Cyclin D3 
 
5’-TGCGTGCAAAAGGAGATCAA-3’  
5’-TCACACACCTCCAGCATCCA-3’  
59.0     
59.7 
Cyclin E1 
 
5’-TGCTACTTGACCCACTGGACTCT-3’  
5’-TGGCGTGGCCTCCTTAAC-3’ 
58.9 
58.2 
p15/INK4B 
 
5’-TGGGAAACCTGGAGAGTAGATGA-3’  
5’-GAATCCCCACACATGACAGTACA-3’  
58.7 
58.3 
p16/INK4A 
 
5’-CTCAACTACGGTGCAGATTCGA-3’  
5’-CACCGGGCGGGAGAA-3’  
59.0 
58.5 
p21/Cip1 
 
5’-TGTGGCTCCCTCCCTGTCT-3’  
5’-GCAGGGTGCTGTCCCTTCT-3’ 
59.2 
58.8 
p27/Kip1 
 
5’-CCTGGCTCTGCTCCATTTGA-3’ 
5’-ACGGATGGAGCGCAAAAC-3’ 
59.9 
58.2 
p53 
 
5’-GCATCCCGTCCCCATCA-3’  
5’-GGATTGTGTCTCAGCCCTGAA-3’  
59.8 
58.7 
Rb 
 
5’-GGTCTGCCAACACCCACAA-3’ 
5’-GATGTCCCAAATGATTCACCAA-3’  
58.9 
58.2 
PTEN 
 
5’-GGTTCTTGGAAAACGGTGCTTAT-3’ 
5’-TGAAACCTCCCATGTGCTGAT-3’  
59.4 
59.0 
β2 microglobulin 
 
5’-GCTATCCAGAAAACCCCTCAA-3’ 
5’-CATGTCTCGATCCCAGTAGACGGT-3’ 
62.0 
62.0 
 
The primers were designed using the mouse cDNA sequences in the UniGene database, 
following the criteria established by the Primer Express software (Applied Biosystems, 
California, USA). 
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